glp-1 shortage news november 2025 Market to Reach $180 Billion by 2035 at 8.7% CAGR What's next for GLP-1 innovation:

Learn how this peptide hormone evolved from diabetes research into a personalized precision medicine tool

A recent study found that stopping GLP-1s, such as Ozempic or Wegovy, can reverse the cardiovascular benefits they provide

Farxiga (Dapagliflozin) is a medication used to treat type 2 diabetes and more

But heres what often gets overlooked: your body already makes this hormone on its own

The Bottom Line The level of difficulty in the modern launch environment is unforgiving

Therefore, there is a need to identify those potential changes and adjust patients medication doses in order to achieve higher efficacy and avoid toxicity.